Novo Nordisk A/S (NYSE:NVO) Stock Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on August 29th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 28th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Southern (NYSE:SO) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 8/28/2025.
• Purchased $15,001 – $50,000 in shares of Exelon (NASDAQ:EXC) on 8/28/2025.
• Purchased $15,001 – $50,000 in shares of Ryman Hospitality Properties (NYSE:RHP) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 8/28/2025.

Novo Nordisk A/S Stock Up 0.7%

Shares of NVO opened at $56.51 on Tuesday. The stock has a market cap of $252.29 billion, a price-to-earnings ratio of 15.52, a P/E/G ratio of 1.96 and a beta of 0.66. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74. The company has a 50-day moving average price of $60.46 and a two-hundred day moving average price of $68.12.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a report on Wednesday, August 13th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 20th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $81.00.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC raised its stake in shares of Novo Nordisk A/S by 0.3% during the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after buying an additional 63,341 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Novo Nordisk A/S by 8.1% during the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company’s stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 1.5% during the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after buying an additional 187,789 shares during the last quarter. Kingstone Capital Partners Texas LLC raised its stake in shares of Novo Nordisk A/S by 301,443.6% during the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after buying an additional 10,001,898 shares during the last quarter. Finally, Folketrygdfondet raised its stake in shares of Novo Nordisk A/S by 6.9% during the first quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock worth $661,202,000 after buying an additional 617,974 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.